PurpleLab Accelerates Clinical Trial Lifecycle with Real-World-Data
Jason Gagner (Vice President of Product for Life Science, PurpleLab) talks about clinical trial variables and how PurpleLab is working to maintain patient retention and accelerate site feasibility.
Approximately 80% of clinical trials will face delays at some point in the trial process. Jason Gagner talked with ACT about how PurpleLab uses real-world data to better inform trials and improve their success rates.
Learn More About:
- Utilizing real-world data (RWD) to assist clinical trials achieve key milestones
- Employing a criteria specific geographic analysis of patient populations to expedite site feasibility assessments
- Understanding the impact of diversity, equity, and inclusion (DEI) in clinical trials on meeting trial objectives and timelines
- Integrating social determinants of health (SDOH) data to minimize patient dropout rates
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
